4.7 Article

Opposing roles of TGFβ and BMP signaling in prostate cancer development

Journal

GENES & DEVELOPMENT
Volume 31, Issue 23-24, Pages 2337-2342

Publisher

COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.307116.117

Keywords

PTEN; SMAD4; TGFBR2; BMPR2; prostate cancer; bone metastasis

Funding

  1. Clayton and Modesta Williams Cancer Research Fund
  2. MD Anderson Cancer Center [P30CA016672]
  3. Department of Defense Prostate Cancer Research Program (PCRP) [W81XWH-14-1-0576]
  4. Indiana Clinical and Translational Sciences Institute (CTSI) - National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award [KL2TR001106, UL1TR001108]
  5. [R01 CA084628]
  6. [P01CA117969]

Ask authors/readers for more resources

SMAD4 constrains progression of Pten-null prostate cancer and serves as a common downstream node of transforming growth factor beta (TGF beta) and bone morphogenetic protein (BMP) pathways. Here, we dissected the roles of TGF beta receptor II (TGFBR2) and BMP receptor II (BMPR2) using a Pten-null prostate cancer model. These studies demonstrated that the molecular actions of TGFBR2 result in both SMAD4-dependent constraint of proliferation and SMAD4-independent activation of apoptosis. In contrast, BMPR2 deletion extended survival relative to Pten deletion alone, establishing itspromoting role in BMP6-driven prostate cancer progression. These analyses reveal the complexity ofTGF beta-BMPsignaling and illuminate potential therapeutic targets for prostate cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available